hotspot -WSS

hotspot

author：Wikipedia 2025-10-01 12:35:30 - browse：254

Biotech startup Generate Biomedicines, which uses artificial intelligence to find new drugs, raised $273 million in a Series C funding round from investors including pharma company Amgen and the VC arm of AI giant NVIDIA.

Generate was founded in 2018 by venture-creation firm Flagship Pioneering to use machine learning algorithms to identify antibodies, peptides, cell therapies, and other medicines. It launched its first clinical trial in July for a Covid monoclonal antibody, and is working on starting another clinical trial for an asthma treatment.

The biotech, which is based in Somerville, Mass., has big plans for the next couple of years: It has another 15 drug candidates in the works and plans to introduce 10 more annually, CEO Mike Nally told STAT.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Dramatically reducing cancer deaths requires the PASTEUR Act

hotspot

WSS

The drug industry sees a key ally in the Senate prevail

Making AI in medicine accessible to smaller, and rural hospitals

Google says AlphaFold 3 can map a vast universe of biomolecules

Google says AlphaFold 3 can map a vast universe of biomolecules

Making AI in medicine accessible to smaller, and rural hospitals

Apple Watch's A

Wikipedia

hotspot

explore

At least 13 dead in Texas as scorching temps continue

After gene therapy, two congenitally deaf children hear for the first time

Psychedelics group wrestles with new pharma identity

Attacks on the drug industry will lead to fewer breakthroughs

At least 13 dead in Texas as scorching temps continue

First recipient of genetically engineered pig kidney has died

Medical records are filled with copy

Google says AlphaFold 3 can map a vast universe of biomolecules

How to save PrEP access — and even expand it

What Mike Pence has said that could be used in a Donald Trump trial

focus

Elevance, private equity launch primary care company

Shionogi licenses Pompe disease therapy from Maze Therapeutics

First recipient of genetically engineered pig kidney has died

H5N1 bird flu: what we're starting to learn about infection in cows

Gilgo Beach: Police identify another victim in serial killing investigation

How to improve immunocompromised access to mAb treatments

leisure time

focus

hotspot

hotspot